Gannon C. K. Mak

Dr. Gannon C. K. Mak

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
GMGannon C. K. Mak
Gannon C. K. Mak
PCPeter Kc Cheng
Peter Kc Cheng
SLStephen Sy Lau
Stephen Sy Lau
KWKitty Ky Wong
Kitty Ky Wong
CLCs Lau
Cs Lau
DTDominic Nc Tsang
Dominic Nc Tsang

10 November 2006 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
JGJ. Gao
J. Gao
LLL. Li
L. Li
PHPak-Leung HO
Pak-Leung HO
GMGannon C. K. Mak
Gannon C. K. Mak
HGHongwei Gu
Hongwei Gu
Bing XuBing Xu
Bing Xu

23 February 2015 in Antiviral Research
Verified
Journal Article
Open access
ETEmi Takashita
Emi Takashita
AMAdam Meijer
Adam Meijer
ALAngie Lackenby
Angie Lackenby
LGLarisa Gubareva
Larisa Gubareva
HAHelena Rebelo De Andrade
Helena Rebelo De Andrade
MTMasato Tashiro
Masato Tashiro
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013-2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.

1 December 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
GMGannon C. K. Mak
Gannon C. K. Mak
SLStephen Sy Lau
Stephen Sy Lau
KWKitty Ky Wong
Kitty Ky Wong
NCNancy Ls Chow
Nancy Ls Chow
CLCs Lau
Cs Lau
DTDominic Nc Tsang
Dominic Nc Tsang

15 March 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
XZXiaofen Zhong
Xiaofen Zhong
HYHuanghao Yang
Huanghao Yang
ZGZu-Feng Guo
Zu-Feng Guo
WSWan-Yee Fion Sin
Wan-Yee Fion Sin
WCWei Chen
Wei Chen
ZGZhihong Guo
Zhihong Guo
Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel strain of coronavirus. Examination of the immune responses of patients who have recovered from SARS should provide important information for design of a safe and effective vaccine. We determined the continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS patients through biopanning with a vast M13 phage display dodecapeptide library. These epitopes converged to very short peptide fragments, one on each of the structural proteins spike and nucleocapsid and the nonstructural proteins 3a, 9b, and nsp 3. Immunoassays found that most of the patients who had recovered from SARS developed complementary antibodies to the epitope-rich region on the spike S2 protein, indicating that this is an immunodominant site on the viral envelope comprising the spike, matrix, and small envelope glycoproteins. These S2-targeting antibodies were shown to effectively neutralize the coronavirus, indicating that they provided protective immunity to help the patients recover from the viral infection. These results suggest that the SARS coronavirus might have an antigenic profile distinct from those of other human or animal coronaviruses. Due to the tested safety and protective effects of the convalescent-phase serological antibodies, identification of their complementary antigens may enable the design of an epitope-based vaccine to prevent potential antibody-mediated immunuopathology.

2 January 2012 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
GMGannon C. K. Mak
Gannon C. K. Mak
AWAnn H. Wong
Ann H. Wong
WHWinnie Y. Y. Ho
Winnie Y. Y. Ho
WLWilina Lim
Wilina Lim
Please cite this paper as: Mak et al. (2012) The impact of pandemic influenza A (H1N1) 2009 on the circulation of respiratory viruses 2009–2011. Influenza and Other Respiratory Viruses 6(3), e6–e10.Surveillance of respiratory viruses has been conducted for many years at the public health laboratory in Hong Kong. With the occurrence of pandemic influenza A (H1N1) 2009, we observed a change in the seasonality of influenza activity with a seemingly corresponding change in the activity of respiratory syncytial virus, parainfluenza virus, and adenovirus during 2009–2011. This phenomenon could most likely be explained by virus interference.